Mauritius to receive consignment of Indian-made coronavirus vaccine Covaxin

Mauritius will receive a consignment of Covaxin, India's indigenously developed Covid-19 vaccine, on Friday, announced the High Commission of India in Port Louis on Thursday

Covaxin
Covaxin
ANI Others
2 min read Last Updated : Mar 19 2021 | 8:16 AM IST

Mauritius will receive a consignment of Covaxin, India's indigenously developed COVID-19 vaccine, on Friday, announced the High Commission of India in Port Louis on Thursday.

Taking to Twitter, the High Commission said that India stands strong with Mauritius in the tough times, describing it as 'a time-tested and enduring partnership'.

"Mauritius arms itself with COVAXIN, India's indigenously developed vaccine, in its fight against COVID19. India stands strong with Mauritius in these tough times. Consignment to arrive tomorrow. A time-tested and enduring partnership," tweeted India in Mauritius.

The Indian High Commission in Mauritius also said that Covaxin is effective against the UK variant and other heterologous strains.

"Developed & manufactured by @BharatBiotech, COVAXIN has demonstrated 81% interim efficacy in preventing COVID19. COVAXIN is effective against UK variant strain & other heterologous strains. EUA received in 8 countries till date, 20 more to follow," it said in another tweet.

Under the 'Vaccine Maitri' initiative, India has been providing coronavirus vaccines to its neighbouring countries.

On Wednesday, External Affairs Minister S Jaishankar under the 'Vaccine Maitri' programme, 72 countries were given vaccines including Maldives, Bhutan, Bangladesh, Nepal, Sri Lanka and Myanmar, as also Mauritius, Seychelles and Gulf nations.

He also said that India has provided medical supplies to 150 nations during the COVID-19 pandemic, out of which 82 were given as grants.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusIndia mauritius tiesMauritiusCoronavirus Vaccine

First Published: Mar 19 2021 | 8:08 AM IST

Next Story